Natrecor: profile and news

Xaliproden May Reduce Side Effect Caused by Eloxatin® in ... Feb 6, 2006
...trials, appears to reduce the risk of peripheral neuropathy, a common side effect associated with the use of the chemotherapy agent Eloxatin® (oxaliplatin) in ... - Cancer Consultants (press release),

Doxil®/Eloxatin® May Provide a Treatment Option in Advanced ... Feb 6, 2006
...published in Gynecologic Oncology, the chemotherapy combination consisting of Doxil® (pegylated liposomal doxorubicin) plus Eloxatin® (oxaliplatin) may ... - Cancer Consultants (press release),

Patients Of UK's Second Biggest Killer To Gain Access To ... Feb 28, 2006
NICE) published their Final Appraisal Determination (FAD), which advocates the use of the potentially life-saving treatment Eloxatin (oxaliplatin) in ... - Medical News Today (press release),

GEMOX Active in Recurrent Pancreatic Cancer Feb 24, 2006
...recently published in the British Journal of Cancer, the chemotherapy combination consisting of Gemzar® (gemcitabine) plus Eloxatin® (oxaliplatin), referred ... - Cancer Consultants (press release),

Roche Stops Recruiting Patients for Avastin Study (Update4) Feb 13, 2006
The arm of the study that looked at Avastin in combination with Roche's Xeloda and Sanofi-Aventis SA's Eloxatin drugs had a higher number of deaths than two ... - Bloomberg

Roche Stops Recruiting Patients for Avastin Study (Update7) Feb 13, 2006
One involved combining Avastin with Roche's Xeloda and Sanofi-Aventis SA's Eloxatin, one involved using Avastin with so-called FOLFOX-4 therapy and one used ... - Bloomberg

Roche Stops Recruiting Patients for Avastin Study (Update8) Feb 13, 2006
One involved combining Avastin with Roche's Xeloda and Sanofi-Aventis SA's Eloxatin, one involved using Avastin with a combination of drugs called Folox-4 and ... - Bloomberg

MRI Contrast Agent Enhances Chemotherapy's Cancer Killing Feb 15, 2006
Cancer Institute. The drugs were Taxol (paclitaxel), Taxotere (docetaxel), Eloxatin (oxaliplatin), and 5-fluorouracil (5FU). In ... - MedPage Today,

Sanofi-Aventis' Battered Charm Mar 1, 2006
Key brands, such as Plavix, Taxotere and Eloxatin oncology treatments, Lantus antidiabetes agent, and Avapro -- an antihypertensive -- will likely drive the ... - BusinessWeek

Sanofi to Introduce Acomplia as Diet Pill This Year (Update3) Feb 23, 2006
Products that are at risk include the cancer drugs Eloxatin and Taxotere as well as Plavix and Avapro, for high blood pressure. ... - Bloomberg

FDA Wants Drug Inserts Patients Can Understand Feb 21, 2006
Lumen Diameter.". A pamphlet included with the cancer treatment Eloxatin is twice as long and at least twice as complex. Simply put ... - International News Service,

Sanofi expects Acomplia launch in 06; profits up Feb 24, 2006
...drugs, Plavix (clopidogrel) and Lovenox (enoxaparin), while other big sellers such as the cancer drugs Taxotere (docetaxel) and Eloxatin (oxaliplatin) and ... - Pharma Times (subscription),

Roche halts enrollment in Avastin trial Feb 13, 2006
...occurred in patients taking a combination of Avastin and Xelox (Roche's Xeloda [capecitabine] plus Sanofi-Aventis' cancer drug Eloxatin [oxaliplatin]) compared ... - Pharma Times (subscription),

Debiopharm SA Presented Results of a Double-Blind Placebo ... Feb 9, 2006
Debiopharm has developed and registered three products with combined sales in excess of $2.2bn in 2005: Eloxatin(R), one of sanofi-aventis' leading marketed ... - Canada NewsWire (press release),

Breakthrough In The Design Of New Drugs - New Way Of Recognising ... Feb 17, 2006
Three further platinum drugs (carboplatin - trade name ‘Paraplatin', nedaplatin and most recently oxaliplatin - trade name Eloxatin) are also in clinical use ... - Medical News Today (press release),

Sanofi 4Q overshadowed by impending legislation Feb 1, 2006
Sales increased by 47.5 per cent to $1.47 billion. Eloxatin, for colorectal cancer, gained a 31 per cent increase in sales to $1.89 billion. ... - In-PharmaTechnologist.com,

Debiopharm SA Presented Results of a Double-Blind Placebo ... 09 Feb 2006
Debiopharm has developed and registered three products with combined sales in excess of $2.2bn in 2005: Eloxatin®, one of sanofi-aventis' leading marketed ... - Yahoo! News (press release)

Sanofi-Aventis 4Q Pharma Result In-Line -SG Jan 30, 2006
However, the market might be concerned by the rest of Pharma's decline and, in the US, persistent weak growth of Taxotere and slowdown of Eloxatin." Stock -0.9 ... - New Ratings

Sanofi-aventis Posts Dynamic Growth in 2005 Full-Year Consolidated ... Jan 30, 2006
2005 as a whole, sales growth in Europe was boosted by a dynamic performance across the entire portfolio, especially Lantus® (up 40.5%), Eloxatin® (up 31.4 ... - Yahoo! News (press release)

Genta Appoints Seasoned Pharma Executive, Lloyd Sanders, as Vice ... Jan 17, 2006
Most recently, Mr. Sanders was Vice President, Oncology Sales, at Sanofi-Aventis, where he led the Eloxatin(R), Taxotere(R), and ELITEK(R) sales teams. ... - PharmaLive.com (press release),

Millennium Announces Appointments of Executive Vice President of ... Jan 25, 2006
...to the Company from sanofi-aventis, where he led the US oncology business unit, a $2 billion business with blockbuster brands such as Eloxatin® and Taxotere ... - Yahoo! News (press release)

Sanofi Q4 sales up 7 pct, raises 2005 EPS forecast Jan 29, 2006
Growth was driven by Plavix and Lovenox, though sales came in below expectations, cancer treatments Eloxatin and Taxotere and Sanofi's vaccines business, which ... - MSN Money

Drugmakers' 4Q Profit, Revenue Rises Jan 30, 2006
...and 18.3 percent sales rise. Other growth drivers included cancer treatments Eloxatin and Taxotere. Sanofi-Aventis said it expects ... - Houston Chronicle,

Sanofi raises growth goal, obesity pill on track Jan 30, 2006
...sales growth was driven by bloodthinners Plavix and Lovenox -- though their sales came in below the Reuters consensus -- cancer drugs Eloxatin and Taxotere and ... - Reuters

Drugmakers‘ 4Q Profit, Revenue Rises Jan 30, 2006
...percent and 18.3 percent sales rise. Other growth drivers included cancer treatments Eloxatin and Taxotere. Last week, the US Food ... - Leading The Charge,

ASCO-GI: Serotonin Receptor Agonist Blocks Neuropathy in Colon ... Jan 30, 2006
...a phase III trial presented at the ASCO/ASTRO Gastrointestinal Cancer symposium, the 325 patients who were randomized to six months of Eloxatin (oxaliplatin), 5 ... - MedPage Today,

Xeloda®/Eloxatin®/Avastin® (XeloxA) Highly Active in Newly ... Nov 18, 2005
...remission rate for patients with metastatic colorectal cancer following treatment with treatment with Xeloda (capecitabine) and Eloxatin (oxapliatin) and ... - Cancer Consultants (press release),

Xeloda®/Eloxatin®/Avastin® Appears Promising for Metastatic ... Nov 9, 2005
2005 European Cancer Conference (ECCO 13), the treatment combination including the chemotherapy agents Xeloda® (capecitabine) and Eloxatin® (oxapliatin) in ... - Cancer Consultants (press release),

Sanofi-aventis Third Quarter 2005: Adjusted EPS(1) up 27.4%, Net ... Nov 7, 2005
Change on a net sales comparable 9-month comparable basis net sales basis Lovenox(R) 551 +13.8% 1,571 +15.7% Plavix(R) 534 +22.8% 1,508 +21.4% Eloxatin(R) 422 ... - PR Newswire (press release),

Universal Adjuvant Chemotherapy Use Is Elusive for Advanced Colon ... Dec 6, 2005
...but the researchers suggested that studies are needed to see if newer regimens - using such drugs as Camptosar (irinotecan) or Eloxatin (oxaliplatin) - might ... - MedPage Today,

Pharma Reformulates Dec 5, 2005
...for non-Hodgkin's lymphoma; Novartis' Gleevec for chronic myeloid leukemia and gastrointestinal stromal tumors (GISTs); Sanofi-Aventis' Eloxatin, licensed from ... - Chemical & Engineering News

Sanofi-aventis Third Quarter 2005: Adjusted EPS(1) up 27.4%, Net ... Nov 7, 2005
Europe, third-quarter sales growth was propelled by a strong showing from the entire portfolio, and in particular from Lantus® (up 44.5%), Eloxatin® (up 27.7 ... - Yahoo! News (press release)

Drug sales lift Sanofi-Aventis prifit Nov 8, 2005
The third-quarter results were boosted by strong increases in sales of cancer treatment Eloxatin, as well as anti-stroke drug Plavix, the company's second ... - BusinessWeek

Sanofi-Aventis beats forecasts Nov 8, 2005
...respectively. The next top two sellers, chemotherapy drugs Taxotere and Eloxatin, also grew strongly, as did Lantus, a diabetes drug. ... - MSNBC

Profit Rises 29% at Sanofi Nov 8, 2005
Sales of the cancer treatment Eloxatin rose 28 percent, to 422 million euros, while revenue for the antistroke drug Plavix increased 23 percent, to 534 million ... - New York Times,

Sanofi-Aventis Profit Up Before Costs Nov 8, 2005
...of Aventis. It reported strong increases in sales of cancer treatment Eloxatin, as well as anti-stroke drug Plavix. It compared ... - Leading The Charge,

Company News Nov 12, 2005
Rising demand for Eloxatin, a colon-cancer treatment, highlights the strength of the company’s anti-cancer drugs, free from immediate threat of potential ... - Business Online,

Sanofi-Aventis adj. profit climbs 29% Nov 8, 2005
Other drugs that helped drive top-line growth included chemotherapy treatment Eloxatin, which had 28.3% growth to 422 million euros; breast cancer drug Taxotere ... - MarketWatch

Sanofi-Aventis shares end higher on profit rise Nov 8, 2005
Other drugs that helped drive top-line growth were: chemotherapy treatment Eloxatin, which had 28.3% growth to 422 million euros; breast cancer drug Taxotere ... - Investor's Business Daily (subscription)

TroVax® Vaccine May Improve Outcomes in Metastatic Colorectal ... Oct 17, 2005
The chemotherapy agents Camptosar® (irinotecan), Eloxatin® (oxaliplatin), and 5-FU (fluorouracil) are standard agents used as part of the treatment strategy. ... - Cancer Consultants (press release),

Antigenics Reports Third Quarter 2005 Financial Results and Recent ... Oct 27, 2005
Aroplatin is similar to Eloxatin(R) (oxaliplatin, Sanofi Aventis), which had global sales of approximately $1.5 billion in 2004. ... - Business Wire (press release),

Treatment Advances For Lymphoma Have Reduced Deaths By 70% Oct 20, 2005
...investigators are leading a national study, called TREE-2, which will evaluate the safety and efficacy of three regimens of Eloxatin plus fluoropymidine, plus ... - Science Daily (press release)

Fears of 'overcaution' by FDA after Vioxx woes go unfounded Sep 21, 2005
For example, in 2002 the FDA approved the colorectal cancer drug Eloxatin just days after Sanofi-Synthelabo submitted the last part of its application. ... - Boston Globe,

Gain Insight into the Current Challenges and Commercial ... Sep 22, 2005
This is most prominent due to the introduction of three novel cytotoxic agents - Xeloda, Camptosar, and Eloxatin - and the recent approval of the two ... - Business Wire (press release),

Debiovision inc, formerly H3 Pharma, a speciality pharmaceutical ... Sep 15, 2005
Debiopharm has developed and registered three products with combined sales in excess of $1.8bn 2004: Eloxatin(R), one of Sanofi-Aventis' leading marketed ... - Canada NewsWire (press release),

The Japanese Cancer Association (JCA) and Debiopharm Present the ... Sep 20, 2005
Debiopharm has developed and registered three products with combined sales in excess of $1.8bn in 2004: Eloxatin®, one of sanofi-aventis' leading marketed ... - Yahoo! News (press release)